XRP News Today: SWIFT Talks, Spot ETF Bets Fuel XRP Adoption Speculation
Ripple eyes favorable terms in cross-appeal talks. A SWIFT deal and spot ETF approval may drive XRP past key resistance and ...
PathAI Announces EMA Qualification for AIM-MASH AI Assist, a Groundbreaking AI Tool for MASH Clinical Trials
PathAI, a global leader in AI-powered pathology, today announced that the European Medicines Agency (EMA) Committee for ...
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease
Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory ...
pharmaphorum1d
EMA panel endorses AI for MASH clinical trials
AI-powered digital pathology specialist PathAI, based in Boston in the US, said that AIM-NASH AI Assist is designed to assist ...
pharmaphorum1d
When measuring European regulatory approval, the timestamp matters
When comparing the FDA and EMA, we found that many of the calculations that determine this relative speed have used time of approval and time of market authorization, interchangeably. This ...
Science Daily2d
New data on Mpox vaccine effectiveness
A study has found that a single dose of the Imvanex vaccine provides protection against Mpox with 84% effectiveness. For people with HIV, however, a single dose of the vaccine fails to offer ...
Traumatic Brain Injury Drug Market 2034: Clinical Trials, EMA, PDMA, FDA Approval, Medication, Epidemiology, Therapies and Companies by DelveInsight
Traumatic Brain Injury companies include Supernus Pharmaceuticals, Inc., Hope Biosciences, The SanBio Group, Merz ...
EurekAlert!4d
Charité study yields new data on Mpox vaccine effectiveness
Universitätsmedizin Berlin has found that a single dose of the Imvanex vaccine provides protection against Mpox with 84% ...
PipelineReview.com1d
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
EAST HANOVER, NJ, USA I March 20, 2025 I Novartis today announced that oral Fabhalta® (iptacopan) has received U.S. Food and Drug Administration (FDA) ...